Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand?

• Published in: Drug discovery today 2019-09, Vol.24 (9), p.1845-1853
• Main Authors: Gonçalves, Elaine D., Dutra, Rafael C.
• Format: Article
• Language: English
• ISSN: 1359-6446; 1878-5832
• DOI: 10.1016/j.drudis.2019.05.023

[Display omitted] •CB1 and CB2 receptors are essential for innate and adaptive immune responses.•The ECS and associated receptors are involved in autoimmune diseases.•CB2R agonists have emerged as new strategies for autoimmunity diseases.•Δ9-THC and CBD showed immunosuppressive activity. Described during the late 1980s and 1990s, cannabinoid receptors (CB1R and CB2R) are G-protein-coupled receptors (GPCRs) activated by endogenous ligands and cannabinoid drug compounds, such as Δ9-THC. Whereas CB1R has a role in the regulation of neurotransmission in different brain regions and mainly mediates the psychoactive effects of cannabinoids, CB2R is found predominantly in the cells and tissues of the immune system and mediates anti-inflammatory and immunomodulatory processes. Studies have demonstrated that CB1R and CB2R can affect the activation of T cells, B cells, monocytes, and microglial cells, inhibiting proinflammatory cytokine expression and upregulating proresolution mediators. Thus, in this review, we summarize the mechanisms by which CBRs interact with the autoimmune environment and the potential to suppress the development and activation of autoreactive cells. Finally, we highlight how the modulation of CB1R and CB2R is advantageous in the treatment of autoimmune diseases, including multiple sclerosis (MS), type 1 diabetes mellitus (T1DM) and rheumatoid arthritis (RA).